Immix Biopharma (Nasdaq: IMMX) Alternatives & Competitors

12 companies similar to Immix Biopharma (Nasdaq: IMMX) — Autoimmune CAR-T Clinical Trailblazer. CAR-T cell therapy for AL Amyloidosis and...

Arcellx

Arcellx is a clinical-stage biotechnology company based in Redwood City, California

224 Acquired $8.43B

Redwood City, United Stat...

Biopharma Biotechnology +3

Autolus Therapeutics

Focused on the development of precisely targeted, controlled & highly active T cell therap...

720 Post-IPO Equity $1.07B

London, United Kingdom

Biopharma Biotechnology +1

Cartesian Therapeutics

Cartesian | Developing potent, safer cell and gene therapies for cancer and autoimmune dis...

4 IPO $132.00M

Biotechnology

Gracell Biotechnologies

A Member of the AstraZeneca Group

33 Acquired $1.29B

Shanghai, China

Biotechnology Health Care

Track all Immix Biopharma (Nasdaq: IMMX) competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Legend Biotech

Multinational biopharmaceutical company focused on discovering and developing cutting-edge...

2565 $1.62B

Somerset, United States

Biotechnology Health Care +2

Emmaus Life Sciences, Inc

Improving the lives of people with rare disease.

36 Seed

Torrance, United States

Biopharma Biotechnology +3

Solid Biosciences

#TogetherWeAreSolid

161 Post-IPO Equity $610.30M

Boston, United States

Biotechnology Health Care

Umoja Biopharma

Pioneering advanced immunotherapies to empower the body's innate ability to fight cancer b...

9 Series C $363.00M

Biopharma Biotechnology +2

Allogene Therapeutics

A biotechnology company catalyzing cancer treatment through the development of CAR T thera...

214 IPO $1.05B

South San Francisco, Unit...

Biotechnology

Caribou Biosciences

Clinical-stage biopharmaceutical company developing transformative therapies to treat deva...

128 IPO $588.55M

Berkeley, United States

Biotechnology Health Care +1

BioSyngen

A clinical stage biotech developing first-in-class cell therapies targeting solid and liqu...

15 Venture round $500.00M

Singapore

Biotechnology

Targazyme

11 Series A $60.00M

Biopharma Biotechnology +2

About Immix Biopharma (Nasdaq: IMMX)

Immix Biopharma (Nasdaq: IMMX), a clinical-stage biopharmaceutical innovator, is pioneering the development of cell therapies targeting AL Amyloidosis and other autoimmune disorders. Their flagship product, the CAR-T cell therapy NXC-201, holds FDA IND clearance and is currently under evaluation in the Phase 1b/2 NEXIC...

Services

Development of CAR-T therapies, Clinical trials for AL Amyloidosis, Research in cell therapy technologies, Regulatory compliance and approvals

Target Customers

Patients with relapsed/refractory AL Amyloidosis, Biopharma investors, Healthcare institutions, Medical professionals

Taxonomy

Immunotherapy, CAR-T Cell Therapy, Autoimmune Diseases, AL Amyloidosis, Biopharmaceutical, Cell Therapy, Clinical-stage Biopharmaceutical Company, Next Generation CAR-T, Phase 1b/2 Clinical Trial, Orphan Drug Designation, Inflammation-driven Diseases, Cancer Treatment, FDA IND Clearance, NEXICART-1, Biotech Company

Frequently Asked Questions

Companies similar to Immix Biopharma (Nasdaq: IMMX) include Arcellx, Autolus Therapeutics, Cartesian Therapeutics, Gracell Biotechnologies, Legend Biotech. They work in Biotechnology and share Immix Biopharma (Nasdaq: IMMX)'s focus on cell therapy, cancer treatment and immunotherapy.

Bounce Watch lists 12 companies that share Immix Biopharma (Nasdaq: IMMX)'s industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches Immix Biopharma (Nasdaq: IMMX) and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Immix Biopharma (Nasdaq: IMMX) Profile Arcellx Alternatives Autolus Therapeutics Alternatives Cartesian Therapeutics Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Immix Biopharma (Nasdaq: IMMX) on 9 Jun 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 29 Sep 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.